Today's Research on Mylan and Watson Pharmaceuticals: One Drug
Maker's Sorrow is Another One's Joy
LONDON, January 18, 2013 /PRNewswire/ --
The patent cliff
has seen many drug majors lose their exclusivity on blockbuster
drugs to generic makers in the past years and this trend is
expected to go for some years to come. In 2012 alone, over 40
branded drugs with a $35 billion
yearly sales tag have lost patent protection. StockCall has
technical coverage on two of the biggest generic makers, Mylan Inc.
(NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is
available for free upon registration at
http://www.stockcall.com/report
The generic drug industry has been feasting on patent
expirations in recent years, and if the start of 2013 is anything
to go on, this year could see more of the same. Major branded drug
companies have lost exclusivity rights to a number of top selling
products, and generic alternatives, as well as customer's pockets,
have been the main beneficiaries.
Mylan only recently announced that it is now releasing its
generic of Pfizer's Dilantin tablets after receiving the FDA's seal
of approval. Dilantin is given for the control of generalized
tonic-clonic (i.e., grand mal) and complex partial (i.e.,
psychomotor, temporal lobe) seizures, and prevention and treatment
of seizures occurring during or following neurosurgery. According
to IMS Health, the 50 mg chewable tablet saw U.S. sales of close to
$16.5 million for a 12 month period
ending September 30, 2012. See our
technical analysis on Mylan by sign up now at
http://www.StockCall.com/MYL011813.pdf
Also in news lately has been Watson Pharmaceuticals Inc.'s [Free
Analysis Report on WPI] [(1)]
generic version of Ferring Pharmaceuticals' Lysteda tablet which
received the FDA's approval even as an infringement lawsuit against
Watson Pharma has been filed by the original maker of the drug.
Whilst this legal battle is still pending, Watson Pharma intends to
make the most of the time to launch its generic version. Last year,
Lysteda saw revenues of close to $25
million in the U.S.
Generic companies also currently have an impressive list of
abbreviated new drug applications awaiting FDA approval. Those that
have first-to-file status have the potential to be even more
lucrative as these companies can enjoy a period of generic
exclusivity that is usually 180 days.
Select generic drug makers have been focusing on expansion of
late, in an attempt to grow sales and profits. Some have been
acquiring competitors, while others have been investing in growing
their presence abroad. Regardless, generic drug companies appear to
be in a strong position to grow in 2013.
Footer:
- Watson Pharmaceuticals Inc. Technical Analysis [
http://www.StockCall.com/WatsonPharmaceuticalsInc011813.pdf ]
About StockCall.com
StockCall.com is a financial website where investors can have
easy, precise and comprehensive research and opinions on stocks
making the headlines. Sign up today to talk to our financial
analyst at http://www.stockcall.com
SOURCE StockCall.com